Liquid Biopsy in Advanced Oligometastatic NSCLC Receiving Surgery

Launched by GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL · Dec 5, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new way to detect and monitor non-small cell lung cancer (NSCLC) in patients who have a limited number of metastases (spread of cancer) and are undergoing surgery. The researchers want to see if a test called liquid biopsy, which looks for cancer DNA in the blood, is a practical option for these patients. This trial is currently recruiting participants who are 18 years or older, generally healthy enough to undergo surgery, and have certain types of cancer spread that can be surgically removed.

To participate, patients need to provide written consent and must be able to follow the study requirements. Those with other serious health issues, past autoimmune diseases, or certain recent medical conditions may not qualify. If eligible, participants can expect to undergo some tests and surgeries and will be monitored closely throughout the study. This trial aims to improve how doctors can manage and treat patients with this specific type of lung cancer, potentially leading to better outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Written informed consent must be obtained from patients and ability for patients to comply with the requirements of the study；
• • Patients must be a man or woman of more than 18 years;
• • ECOG PS ≦1；
• • The function of the organs was evaluated by the surgeon to tolerate local surgical treatment；
• • The classification was evaluated as simultaneous oligometastases at initial treatment or oligoresidual/oligoprogression/oligorecurrence after induction therapy; \[Define: Initial treatment of simultaneous oligometastases: without systemic treatment, at the time of diagnosis, up to 5 metastases and up to 3 organs were involved, excluding pleural metastases or myeloid metastases.
• • Oligoresidual after induction therapy: after systemic therapy, distant metastases were stable or reduced, primary lesions were stable or reduced, PET/CT metabolism was reduced, and no more than 5 residual lesions and no more than 3 organs were involved.
• • Oligoprogression after induction therapy: After systemic therapy, some lesions were stable or reduced, while some original lesions were larger than before.
• • Oligorelapses after induction therapy: after systemic therapy, systemic lesions were stable or reduced, and new local lesions appeared.\]
• • Lesion evaluation can be surgically removed. \[Definition of operable resection: the lesion is limited and can be completely removed through surgery as assessed by the surgeon, with no significant impact on postoperative quality of life. Pulmonary surgical procedures include lobectomy, segmental resection and wedge resection. Pneumonectomy is not included.\]
• Exclusion Criteria:
• • Patients with a confirmed or suspected autoimmune disease;
• • Patients with a history of human immunodeficiency virus (HIV) positive or acquired immunodeficiency syndrome (AIDS);
• • Patients with a history of any arterial thrombosis within 6 months and history of deep vein thrombosis, pulmonary embolism, or any other severe thromboembolism within 3 months;
• • Patients with any unstable systemic disease (eg, active infection, high-risk hypertension, unstable angina, congestive heart failure, etc.);
• • Patients with a history of other malignancies in the past 5 years;
• • Patients identified by the investigators patients with contraindications to local treatment;
• • Patients with serious mental illness;
• • Patients who cannot sign informed consent;
• • Patients who cannot be followed up as scheduled;

Trial Officials